NO20091597L - Puriner som PKC-theta-inhibitorer - Google Patents

Puriner som PKC-theta-inhibitorer

Info

Publication number
NO20091597L
NO20091597L NO20091597A NO20091597A NO20091597L NO 20091597 L NO20091597 L NO 20091597L NO 20091597 A NO20091597 A NO 20091597A NO 20091597 A NO20091597 A NO 20091597A NO 20091597 L NO20091597 L NO 20091597L
Authority
NO
Norway
Prior art keywords
purines
pkc
theta inhibitors
inhibitors
theta
Prior art date
Application number
NO20091597A
Other languages
English (en)
Norwegian (no)
Inventor
Neeltje Miranda Teerhuis
Johannes Petrus Maria Lommerse
Koc-Kan Ho
Jui-Hsiang Chan
Michael Ohlmeyer
Irina Neagu
Celia Kingsbury
Andrew Roughton
David Diller
Jacobus Cornelis Henricus Maria Wijkmans
Original Assignee
Pharmacopeia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Llc filed Critical Pharmacopeia Llc
Publication of NO20091597L publication Critical patent/NO20091597L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20091597A 2006-10-20 2009-04-22 Puriner som PKC-theta-inhibitorer NO20091597L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85339606P 2006-10-20 2006-10-20
PCT/US2007/081899 WO2008051826A2 (en) 2006-10-20 2007-10-19 Purines as pkc-theta inhibitors

Publications (1)

Publication Number Publication Date
NO20091597L true NO20091597L (no) 2009-07-14

Family

ID=39111415

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091597A NO20091597L (no) 2006-10-20 2009-04-22 Puriner som PKC-theta-inhibitorer

Country Status (17)

Country Link
US (1) US20110046131A1 (de)
EP (1) EP2078019A2 (de)
JP (1) JP2010507581A (de)
KR (1) KR20090075854A (de)
CN (1) CN101657453B (de)
AU (1) AU2007309167A1 (de)
BR (1) BRPI0717435A2 (de)
CA (1) CA2666940A1 (de)
CO (1) CO6160294A2 (de)
EC (1) ECSP099342A (de)
IL (1) IL198080A0 (de)
IN (1) IN2009CN02154A (de)
MX (1) MX2009004154A (de)
NO (1) NO20091597L (de)
RU (1) RU2009118963A (de)
WO (1) WO2008051826A2 (de)
ZA (1) ZA200902640B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CN101454325A (zh) * 2006-03-09 2009-06-10 法马科皮亚公司 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂
CN101626765B (zh) * 2006-06-23 2012-12-26 帕拉特克药品公司 转录因子调节化合物及其使用方法
US20120295915A1 (en) * 2009-11-24 2012-11-22 Chaudhari Amita M Azabenzimidazoles as fatty acid synthase inhibitors
AU2011209651A1 (en) * 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
US8697708B2 (en) 2010-09-15 2014-04-15 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
CN103827115A (zh) * 2011-09-20 2014-05-28 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶化合物、组合物和使用方法
CN107106517A (zh) * 2014-08-25 2017-08-29 堪培拉大学 用于调节癌干细胞的组合物及其用途
US11986480B2 (en) 2017-02-03 2024-05-21 Tohoku University Heterocyclic compound
SG11202004167XA (en) * 2017-11-08 2020-06-29 Epiaxis Therapeutics Pty Ltd Immunogenic compositions and uses therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470543A1 (de) * 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung
CN1130363C (zh) * 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
US20050165232A1 (en) * 2002-05-13 2005-07-28 Richard Beresis Phenyl substituted imidaopyridines and phenyl substituted benzimidazoles
JP2004217582A (ja) * 2003-01-16 2004-08-05 Abbott Japan Co Ltd ９ｈ−プリン誘導体
CN101048410B (zh) * 2004-10-29 2010-06-23 泰博特克药品有限公司 抑制hiv的双环嘧啶衍生物
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP1853588B1 (de) * 2005-02-16 2008-06-18 AstraZeneca AB Chemische verbindungen
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
CN101454325A (zh) * 2006-03-09 2009-06-10 法马科皮亚公司 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂

Also Published As

Publication number Publication date
KR20090075854A (ko) 2009-07-09
MX2009004154A (es) 2009-09-09
AU2007309167A1 (en) 2008-05-02
WO2008051826A2 (en) 2008-05-02
JP2010507581A (ja) 2010-03-11
CN101657453B (zh) 2013-06-12
BRPI0717435A2 (pt) 2014-03-18
RU2009118963A (ru) 2010-11-27
WO2008051826A3 (en) 2008-10-02
ECSP099342A (es) 2009-06-30
CA2666940A1 (en) 2008-05-02
IN2009CN02154A (de) 2015-08-07
IL198080A0 (en) 2009-12-24
US20110046131A1 (en) 2011-02-24
CN101657453A (zh) 2010-02-24
CO6160294A2 (es) 2010-05-20
EP2078019A2 (de) 2009-07-15
ZA200902640B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
NO20091597L (no) Puriner som PKC-theta-inhibitorer
WO2009062059A3 (en) Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
UY29612A1 (es) Compuestos quimicos ii
MX2009012612A (es) Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
ATE554065T1 (de) Sulfoniumsalz-fotoinitiatoren
WO2006052568A3 (en) Tgf-beta inhibitors
WO2006133147A3 (en) Organic compounds
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
WO2008109181A3 (en) Metalloprotease inhibitors containing a heterocyclic moiety
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
NO20075809L (no) DNA-PK inhibitorer
MX2009005934A (es) Compuestos organicos.
NO20090541L (no) Prodrug av cinnamidforbindelse
WO2007133352A3 (en) Macrocyclic kinase inhibitors
WO2007109080A3 (en) Deuterated hepatitis c protease inhibitors
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2007105058A8 (en) Pyrazole compounds
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
BRPI0720525B8 (pt) inibidores de mapk/erk quinase
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
NO20084547L (no) Fremgangsmate for fremstilling av HIV-proteaseinhibitorer
EA200900946A1 (ru) Новый способ синтеза агомелатина
WO2008058118A3 (en) Preparation of montelukast and its salts
TW200738621A (en) Chemical process
EA200801884A1 (ru) Новый способ синтеза ранелата стронция и его гидратов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application